Certara, Inc.
A maker of biosimulation software that lets drug developers test medicines in virtual patients before real trials, Certara's tools include Simcyp, Phoenix, and Chemaxon, and are used by researchers and regulators around the world. It was formed in 2008 from the merger of Tripos and Pharsight, two pioneers in molecular modeling and clinical trial simulation. The coined name "Certara" echoes the word certainty — a nod to its aim of making drug development more predictable.
Granted 329.3K · Bought 24.1K · Sold 1.14M
Granted 7.1K · Sold 2.08M
Granted 7.1K
Granted 48.1K · Bought 25.0K · Sold 400.0K
Granted 190.3K · Bought 20.0K · Sold 45.0K
Granted 23.8K · Sold 55.0K
Granted 145.9K · Sold 118.3K
Granted 38.5K · Sold 163.4K
Granted 18.3K · Sold 92.5K
Granted 198.1K · Bought 5.0K · Sold 12.1K
Granted 271.2K · Bought 245 · Sold 200.0K
Granted 11.9K
Granted 145.9K · Sold 256.1K
Granted 143.7K
Granted 59.8K
Granted 51.8K
Granted 51.8K
Granted 45.7K · Bought 5.0K
Granted 35.9K · Sold 69.7K
Granted 45.7K
Bought 42.0K
Granted 56.5K
Granted 26.5K
Granted 34.4K
Granted 24.1K
Granted 17.6K
Granted 10.8K
Granted 7.1K
Granted 5.5K
Sold 89.07M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Feehery William FCHIEF EXECUTIVE OFFICER, Director · 42 transactions | — | 2.36M | 329.3K | 24.1K | 1.14M |
| Slaine Mason PDirector · 17 transactions | — | 660.3Kas of Nov 2022 | 7.1K | — | 2.08M |
| McCoy Sherilyn SDirector · 1 transaction | — | 621.1Kas of May 2021 | 7.1K | — | — |
| Schemick Michael AndrewCHIEF FINANCIAL OFFICER · 16 transactions | — | 514.1Kas of Mar 2023 | 48.1K | 25.0K | 400.0K |
| Cashman James E IIIDirector, Chairman · 10 transactions | — | 484.2K | 190.3K | 20.0K | 45.0K |
| Edge JustinPRES., REGULATORY & ACCESS · 12 transactions | — | 394.8Kas of Apr 2022 | 23.8K | — | 55.0K |
| Aspbury RobertPRESIDENT, PREDICTIVE TECH · 44 transactions | — | 321.7K | 145.9K | — | 118.3K |
| Rayner Craig R.PRESIDENT, INTEGRATED DRUG DEV · 8 transactions | — | 316.0Kas of Sep 2021 | 38.5K | — | 163.4K |
| Choe Jieun W.CHIEF STRATEGY & MARKETING · 12 transactions | — | 248.6Kas of Apr 2022 | 18.3K | — | 92.5K |
| Walsh Matthew MDirector · 9 transactions | — | 213.3K | 198.1K | 5.0K | 12.1K |
| Traynor Richard M.SVP AND GENERAL COUNSEL · 42 transactions | — | 178.8Kas of Apr 2024 | 271.2K | 245 | 200.0K |
| Dickinson JudithSee Remarks · 1 transaction | — | 173.6Kas of Apr 2021 | 11.9K | — | — |
| Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF · 37 transactions | — | 85.0K | 145.9K | — | 256.1K |
| Gallagher John EChief Financial Officer · 18 transactions | — | 62.1K | 143.7K | — | — |
| Resnick Jon MatthewChief Executive Officer, Director · 2 transactions | — | 59.8K | 59.8K | — | — |
| Collins CynthiaDirector · 5 transactions | — | 51.8K | 51.8K | — | — |
| Killefer NancyDirector · 5 transactions | — | 51.8K | 51.8K | — | — |
| Broshy EranDirector, Chairman · 6 transactions | — | 50.7K | 45.7K | 5.0K | — |
| Smith Patrick FPRESIDENT, DRUG DEV SOLUTIONS · 26 transactions | — | 50.1Kas of Oct 2024 | 35.9K | — | 69.7K |
| Crane Rosemary ADirector · 4 transactions | — | 45.7K | 45.7K | — | — |
| McLean Stephen M.Director · 2 transactions | — | 42.0Kas of Aug 2022 | — | 42.0K | — |
| Corcoran DanielSVP and General Counsel · 10 transactions | — | 39.9K | 56.5K | — | — |
| Reynders John V WChief Financial Officer, Director · 2 transactions | — | 26.5K | 26.5K | — | — |
| Sherman Nicolette DCHIEF HUMAN RESOURCES OFFICER · 13 transactions | — | 25.7Kas of Apr 2024 | 34.4K | — | — |
| Anhalt RonaChief Human Resources Officer · 6 transactions | — | 19.0K | 24.1K | — | — |
| Virkler DraytonPRESIDENT, REG & ACCES · 5 transactions | — | 12.4Kas of Mar 2023 | 17.6K | — | — |
| McKemey AdrianPresident, Drug Dev. Solutions · 2 transactions | — | 8.2K | 10.8K | — | — |
| Gallagher Carol GiltnerDirector · 1 transaction | — | 7.1Kas of Jun 2021 | 7.1K | — | — |
| Bedi ArjunDirector · 1 transaction | — | 5.5K | 5.5K | — | — |
| EQT Avatar Parent GP LLC +2 co-filers10% owner · 8 transactions | — | 0as of Dec 2022 | — | — | 89.07M |
Select a row to see that insider’s individual transactions.
Net open-market activity over all recorded history: -93.57M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.